# A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome

> **NCT01880437** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 38 (actual)

## Conditions studied

- Myelodysplastic Syndromes, Myelogenous Leukemia, Acute

## Interventions

- **DRUG:** cytarabine
- **DRUG:** vismodegib

## Key facts

- **NCT ID:** NCT01880437
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01880437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01880437, "A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01880437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*